Pharma: Page 8
-
Courtesy of HLTH 2025
Top RFK aide lashes out against healthcare industry for profiting off of illness
Calley Means stopped short of accusing hospitals, insurers and drug companies from actively working to keep Americans sick, but said it was an "economic fact" that the companies benefit financially when people are ill.
By Susanna Vogel • Oct. 22, 2025 -
Getty Images
China competitionTakeda stakes more than $11B on cancer drugs from China
The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be “transformative” for its oncology portfolio.
By Ben Fidler • Oct. 22, 2025 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Getty Images
News roundupIambic partners with Jazz; Merck breaks ground on $3B plant
The biotechs will assess a combination of two drugs against HER2-positive breast cancer. Elsewhere, Merck unveiled the latest piece of its more than $70 billion domestic manufacturing investment.
By BioPharma Dive staff • Oct. 21, 2025 -
Alamy
Novo’s main shareholder pushes out more than half of company’s board
The Novo Foundation chair said the current board of the Wegovy maker, which is already dealing with layoffs and a CEO change, was too slow to react to obesity market shifts.
By Jonathan Gardner • Oct. 21, 2025 -
AdobeStock/1107050561
Sponsored by PanalgoFrom weeks to minutes: How generative AI transforms pharma data and ROI
GenAI is changing how pharma teams work — making data accessible, transparent, and actionable.
By Niyati Parikh, VP, Product Readiness, Panalgo • Oct. 20, 2025 -
Getty Images
Roche pill delays tumor progression in closely watched breast cancer study
Results presented at the European Society for Medical Oncology meeting could help separate Roche’s medicine from similar hormone-degrading drugs for breast tumors.
By Jonathan Gardner • Oct. 18, 2025 -
Getty Images
J&J claims success in study testing earlier Tecvayli use in multiple myeloma
The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to later-line settings for the persistent blood cancer.
By Jonathan Gardner • Oct. 16, 2025 -
Courtesy of Novartis
Novartis confirms drug’s benefits in rare kidney disease as competitors loom
The findings position Fabhalta to secure a standard approval in IgA nephropathy — a crowded area of drug research — at a time when newer types of medicines are quickly advancing.
By Kristin Jensen • Oct. 16, 2025 -
Courtesy of Novo Nordisk
Novo wagers up to $2.1B on Omeros’ rare disease drug
The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called complement-mediated diseases.
By Delilah Alvarado • Oct. 15, 2025 -
Scott Olson via Getty Images
Obesity drugsLilly, battling skepticism, reinforces GLP-1 pill’s case with new study data
Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where on Wednesday it succeeded in two more late-stage trials.
By Kristin Jensen • Oct. 15, 2025 -
William Walker/BioPharma Dive
Sponsored by Pearson[Podcast] The Progress Profile: Alzheimer’s Research in Focus
Discover the latest breakthroughs in Alzheimer's research, diagnosis, and prevention in this expert-led podcast series.
By BioPharma Dive's studioID • Oct. 15, 2025 -
Courtesy of Johnson & Johnson
J&J plans to spin out orthopedics business
CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such as cardiovascular and robotics.
By Ricky Zipp • Oct. 14, 2025 -
Getty Images
Immune resetBristol’s $1.5B Orbital buyout extends ‘in vivo’ cell therapy deal streak
The acquisition of the well-funded startup is the fourth this year involving companies with technologies that can genetically modify immune cells inside the body.
By Jonathan Gardner • Oct. 10, 2025 -
Getty Images
Boehringer Ingelheim drug wins FDA OK in tough-to-treat lung disease
The clearance makes Jascayd the first new drug for idiopathic pulmonary fibrosis in over a decade, but some analysts see it as a “modest” advance in care.
By Delilah Alvarado • Oct. 8, 2025 -
Ermath, Michael. (2020). "Individualized Therapies Workshop" [Photograph]. Retrieved from Flickr.
Peter Marks, former top FDA vaccine official, joins Eli Lilly
Six months after his abrupt resignation as CBER director, Marks has been hired to run discovery and infectious disease work at the big Indianapolis drugmaker.
By Jonathan Gardner • Oct. 7, 2025 -
Alamy
AstraZeneca, Daiichi drug extends survival in hard-to-treat breast cancer
The results could pave the way for Datroway to supplant chemotherapy in certain triple-negative tumors, adding to existing clearances in other breast and lung malignancies.
By Delilah Alvarado • Oct. 6, 2025 -
Alamy
Amgen claims ‘landmark’ study result that could widen heart drug’s use
In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, which could pave the way for access to a much broader population.
By Jonathan Gardner • Oct. 2, 2025 -
Courtesy of Merck
Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?
Wall Street analysts expect the subcutaneous version of Keytruda, which just launched last week, to help soften the blow when the original loses patent protection later this decade.
By Michael Gibney • Oct. 2, 2025 -
Jacob Bell/BioPharma Dive
Takeda, in reversal, abandons cell therapy research
The Japanese pharmaceutical company, which had made cell therapy a priority a few years ago, aims to partner its work while prioritizing investments elsewhere.
By Delilah Alvarado • Oct. 1, 2025 -
ASCO / Nick Agro
The top biopharma conferences in 2026
Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch next year.
By Ben Fidler • Oct. 1, 2025 -
Win McNamee via Getty Images
Trump administrationTrump, Pfizer drug pricing deal short on details, possible impact
A pact to offer “most favored nation” prices to state Medicaid programs and via direct-to-consumer channels doesn’t affect those on commercial insurance or who won’t pay out of pocket.
By Jonathan Gardner • Sept. 30, 2025 -
Getty Images
Obesity drugsMetsera strengthens case for Pfizer buyout with latest study data
In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing of Eli Lilly’s Zepbound.
By Jonathan Gardner • Sept. 30, 2025 -
Courtesy of GSK Flickr page
Emma Walmsley, big pharma’s first female CEO, to depart GSK
Walmsley, who helped push GSK to focus more exclusively on specialty medicines and oncology, will be succeeded by commercial head Luke Miels on Jan. 1.
By Jonathan Gardner • Sept. 29, 2025 -
Courtesy of Genmab A/S
Genmab to acquire closely watched cancer drug in $8B Merus buyout
The deal hands Genmab a drug that showed the potential in earlier testing to extend survival in head and neck cancer when added to Merck’s widely used immunotherapy Keytruda.
By Delilah Alvarado • Sept. 29, 2025 -
Getty Images
Pharma reshoringKey exemptions could limit impact of Trump’s pharmaceutical tariffs
Carve-outs for generics, European exports and companies onshoring drug production will likely shield most branded drugs from the 100% levies Trump announced Thursday.
By Jonathan Gardner • Sept. 26, 2025
Previous
